Alamar Biosciences, Inc.
ALMR
Sync financial data to generate a health grade for this company.
Analytical Summary
Review the statement evidence below to form a view on ALMR.
3-Year Financial Trajectory
QuarterlyStatement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ |
|---|---|---|---|
| Revenue Growth YoY (%) |
98.9%
Excellent
Excellent
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+1878%)
|
— | — |
| EPS Growth YoY (%) |
-155.9%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-178.4%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
-41.2%
Weak
Weak
Year-over-year change in free cash flow |
— | — |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ |
|---|---|---|---|
| Operating Margin (%) (%) |
-47.4%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-495%)
|
— |
-65.3%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-644%)
|
| Effective Tax Rate (%) (%) |
-2.2%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — |
| Profit Margin (%) (%) |
-81.9%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-1124%)
|
— |
-58.5%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-831%)
|
| FCF Margin (%) (%) |
-80.5%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
— |
-104.1%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
| FCF / Net Income (x) |
0.98x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
1.78x
Excellent
Excellent
Free cash flow relative to reported net income
Optimal:
> 1x
|
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ |
|---|---|---|---|
| Return on Invested Capital (%) |
7.1%
Fair
Fair
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— | — |
| Return on Capital (%) (%) |
-6.6%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — |
| Return on Common Equity (%) (%) |
12.0%
Fair
Fair
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-20%)
|
— | — |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ |
|---|---|---|---|
| Interest Coverage (x) |
-79.15x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
— |
-2851.00x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
| Net Debt (USD) | $-64.59M | $-30.00M | — |
Secondary lens
Benchmark Lens
Compare ALMR against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare ALMR against peers after checking the statement evidence.
Compare ALMR with peers
Stack ALMR against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago